Additionally, serum CHI3L1 levels seemed to predict the CIS conversion to RRMS, and they were also higher in people with progressive disease compared to those with RRMS, confirming its implication with neurodegeneration and disease severity [99,100]. The gene discussed is CHI3L1; the disease is in situ carcinoma.